Equities Analysts Offer Predictions for MNPR FY2027 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities research analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a report released on Wednesday, July 22nd. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($1.35) per share for the year, up from their previous forecast of ($1.37). HC Wainwright currently has a “Buy” rating and a $125.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.82) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2028 earnings at $0.91 EPS, FY2029 earnings at $2.41 EPS and FY2030 earnings at $6.61 EPS.

Several other equities analysts have also commented on MNPR. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Wall Street Zen lowered Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, July 12th. UBS Group set a $125.00 target price on Monopar Therapeutics in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Finally, BTIG Research raised their target price on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Three analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $112.08.

Monopar Therapeutics Stock Performance

Shares of MNPR opened at $109.87 on Friday. Monopar Therapeutics has a 1 year low of $29.18 and a 1 year high of $116.64. The company’s 50 day simple moving average is $80.50 and its 200 day simple moving average is $66.67. The company has a market capitalization of $736.13 million, a price-to-earnings ratio of -57.83 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41.

Hedge Funds Weigh In On Monopar Therapeutics

Several large investors have recently modified their holdings of MNPR. Goldman Sachs Group Inc. acquired a new position in shares of Monopar Therapeutics in the 1st quarter worth approximately $673,000. Jane Street Group LLC acquired a new position in Monopar Therapeutics during the 1st quarter valued at approximately $377,000. Geode Capital Management LLC grew its stake in Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock worth $3,468,000 after buying an additional 48,379 shares during the last quarter. JPMorgan Chase & Co. increased its position in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the period. Finally, Rhumbline Advisers bought a new stake in Monopar Therapeutics in the second quarter valued at $209,000. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.